Company · Public · CDXC
ChromaDex
Consumer-facing NAD+ precursor business with an associated clinical research programme.
Listing
Public
Ticker
CDXC
Headquarters
Los Angeles, US
Founded
1999
Technology
Nicotinamide riboside (consumer NAD+)
Category
Longevity thesis
Consumer revenue funds evidence generation, but the two must be judged separately.
Programmes
- Nicotinamide riboside trialsInvestigator-led
Muscle and cardiometabolic endpoints
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.